News

Vertex plan to build on pain drug breakthrough hits hurdles
The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM ...